Mind Medicine Inc [MNMD] stock is trading at $9.85, down -1.40%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The MNMD shares have gain 16.71% over the last week, with a monthly amount glided 21.60%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Evercore ISI started tracking the stock with Outperform rating on January 28, 2025, and set its price target to $23. On December 20, 2024, Chardan Capital Markets initiated with a Buy rating and assigned a price target of $20 on the stock. ROTH MKM initiated its recommendation with a Buy and recommended $36 as its price target on July 24, 2024. Robert W. Baird started tracking with a Outperform rating for this stock on May 29, 2024, and assigned it a price target of $27. In a note dated April 15, 2024, Leerink Partners initiated an Outperform rating and provided a target price of $20 on this stock.
Mind Medicine Inc [MNMD] stock has fluctuated between $4.70 and $10.44 over the past year. Currently, Wall Street analysts expect the stock to reach $16 within the next 12 months. Mind Medicine Inc [NASDAQ: MNMD] shares were valued at $9.85 at the most recent close of the market. An investor can expect a potential return of 62.44% based on the average MNMD price forecast.
Analyzing the MNMD fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.43, Equity is -0.5 and Total Capital is -0.57. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Mind Medicine Inc’s Current Ratio is 4.98. Further, the Quick Ratio stands at 4.98, while the Cash Ratio is 0.88.
Transactions by insiders
Recent insider trading involved Sullivan Mark, Chief Legal Officer, that happened on Jun 25 ’25 when 11491.0 shares were sold. Chief Medical Officer, Karlin Daniel completed a deal on Jun 25 ’25 to sell 7848.0 shares. Meanwhile, Chief Executive Officer Barrow Robert sold 26491.0 shares on Jun 25 ’25.
